At a glance
ClinicalIndex Comparison RecordN/ACompleted· 19 enrolled
Drug / intervention
Tolcapone +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind Study of Neural Circuit Responses to COMT Inhibitors in PPG
In Brief
A clinical study evaluating Tolcapone and Placebo for Pathological Gambling. Completed, enrolled 19 participants.
Detailed Summary
This study deals with how people decide between rewards of different value. The investigators want to understand how the brain's dopamine system impacts this kind of decision making. The investigators will use a medication, tolcapone, which can temporarily affect the dopamine system.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPathological Gambling
Countries--
CollaboratorsNational Center for Responsible Gaming
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartAug 2014
Primary CompletionSep 2015
First PostedMay 2016
TodayJul 2026
First PostedMay 16, 2016
Enrollment StartAug 1, 2014
Primary CompletionSep 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 10.1 years ago
Interventions
Tolcaponedrug
Tolcapone is in the medication class of catechol-O-methyltransferase (COMT) inhibitors
Placebodrug
A placebo is a tablet or capsule that looks like the study medication (in this case, tolcapone) but does not contain any active ingredients